Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya3374710.26442/00403660.2019.12.000173Editorial articleПередовая статьяReview ArticleHyperuricemia, gout and high cardiovascular risk - how to manage them in clinical practiceГиперурикемия, подагра и высокий кардиоваскулярный риск - как ими управлять в клинической практикеFominV VФоминВ ВMorosovaT EМорозоваТ ЕTsurkoV VЦуркоВ ВSechenov First Moscow State Medical University (Sechenov University)ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)Pirogov Russian National Research Medical UniversityФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России151220199112VOL 91, NO12 (2019)ТОМ 91, №12 (2019)758316042020Copyright ©; 2019, Consilium MedicumCopyright ©; 2019, ООО "Консилиум Медикум"2019Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/33747

In recent years, the relationship of hyperuricemia and gout with a high risk of cardiovascular disease has been widely discussed. Therefore, it is important to systematically examine patients in order to diagnose comorbidities, among which cardiovascular disease and its complications occupy a leading place and consider mandatory treatment of patients with hyperuricemia and gout with high cardiovascular risk with lowering drugs, which fully reflects the provisions of the latest European recommendations for the management and treatment of patients with gout.

Гиперурикемия, подагра и высокий кардиоваскулярный риск - как ими управлять в клинической практике В последние годы широко обсуждается связь гиперурикемии и подагры с высоким риском кардиоваскулярных болезней. Поэтому важно систематически обследовать пациентов с целью диагностики сопутствующих заболеваний, среди которых сердечно - сосудистая патология и ее осложнения занимают ведущее место, и считать обязательным лечение пациентов с гиперурикемией и подагрой с высоким кардиоваскулярным риском уратснижающими препаратами, что полностью отражает положения последних европейских рекомендаций по ведению и лечению пациентов с гиперурикемией и подагрой.

uric acidhyperuricemiagoutcardiovascular diseaseмочевая кислотагиперурикемияподаграсердечно сосудистые болезни с гиперурикемией и высоким кардиоваскулярным рискомRichette P, Doherty M, Pascual E, еt al. EULAR evidence - based recommendations for the management of gout. Ann Rheum Dis. 2016. doi: 10.1136/annrheumdis-2016-209707Zhu Y, Pandya B.J, Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136-41. doi: 10.1002/art.30520Lin К.С, Lin H.Y, Chou R. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27(6):1501-5.Simkin P.A. The pathogenesis of podagra. Ann Intern Med. 1977;86:230-3.Компания «ЭГИС» собрала статистику о распространенности гиперурикемии в сочетании с артериальной гипертензией и сопутствующими заболеваниями среди российских пациентов. Поликлиника. Спецвыпуск. 2017;(4):16.Mazzali M, Hughes J, Kim Y.G, Jefferson J.A, Kang D.H, Gordon K.L, Lan H.Y, Kivlighn S, Johnson R.J. Elevated uric acid increases blood pressure in the rat by a novel crystal - independent mechanism. Hypertension. 2001;38(5):1101-6.Perez-Pozo S.E, Schold J, Nakagawa T, Sanchez-Lozada L.G, Johnson R.J, Lillo J.L. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes (Lond). 2010;34(3):454-61.De Bosch B.J, Kluth O, Fujiwara H, Schurmann A, Moley K. Early - onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. Nat Commun. 2014;5:4642. doi: 10.1038.ncomms5642Feig D.I, Kang D.H, Johnson R.J. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811-21. doi: 10.1056 / NEJMra0800885Richette P, Perez-Ruiz F, Doherty M, Jansen T.L, Nuki G, Pascual E, Punzi L, So A.K, Bardin T. Improving cardiovascular and renal out - comes in gout: what should we target? Nat Rev Rheumatol. 2014;10(11):654-61. doi: 10.1016/j.jare.2017.04.008Andres M, Quintanilla M.A, Sivera F, Sanchez-Paya J, Pascual E, Vela P, Ruiz-Nodar J.M. Silent monosodium urate crystal deposits are associated with severe coronary calcification in asymptomatic hyperuricemia: an exploratory study. Arthritis Rheum. 2016;68(6):1531-9. doi: 10.1002/art.39581Saito Y, Nakayama T, Sugimoto K, Fujimoto Y, Kobayashi Y. Relation of lipid content of coronary plaque to level of serum uric acid. Am J Cardiol. 2015;116(9):1346-50. doi: 10.1016/j.amjcard.2015.07.059Ando K, Takahashi H, Watanabe T, Daidoji H, Otaki Y, Nishiyama S, Arimoto T, Shishido T, Miyashita T, Miyamoto T, et al. Impact of serum uric acid levels on coronary plaque stability evaluated using integrated backscatter intravascular ultrasound in patients with coronary artery disease. J Atheroscler Thromb. 2016;23(8):932-9. doi: 10.5551/jat.33951Park J.J, Roudier M.P, Soman D, Mokadam N.A, Simkin P.A. Prevalence of birefringent crystals in cardiac and prostatic tissues, an observational study. BMJ Open. 2014;4(7):e005308. doi: 10.1136/bmjopen-2014-005308Borghi C, Rosei E.A, Bardin T, Dawson J, Dominiczak A, Kielstein J.T, Manolis A.J, Perez-Ruiz F, Mancia G. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9):1729-41. doi: 10.1097/HJH.0000000000000701Zhao G, Huang L, Song M, Song Y. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and al. l - cause mortality: a meta - analysis of prospective studies. Atherosclerosis. 2013;231(1):61-8. doi: 10.1016/j.atherosclerosis.2013.08.023Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Hibi K, Terashima M, Michishita I. Correlations between serum uric acid and coronary atherosclerosis before and during statin therapy. Coron Artery Dis. 2014;25(4):343-8. doi: 10.1097/MCA.0000000000000084Tamariz L, Hernandez F, Bush A, Palacio A, Hare J.M. Association between serum uric acid and atrial fibrillation: a systematic review and meta - analysis. Heart Rhythm. 2014;11(7):1102-8. doi: 10.1016/j/hrthm.2014.04.003Kim S.Y, Guevara J.P, Kim K.M, Choi H.K, Heitjan D.F, Albert D.A. Hyperuricemia and risk of stroke: a systematic review and meta - analysis. Arthritis Rheum. 2009;61(7):885-92. doi: 10.1002 / art. 24612Harzand A, Tamariz L, Hare J.M. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. Congest Heart Fail. 2012;18(3):179-82. doi: 10.1111/j.1751-7133.2011.00262.x.Bardin T, Richette Р. Impact of comorbidities on gout and hyperuricemia: an updated on prevalence and treatment options. BMC Med. 2017;15:123. doi: 10.1186/s12916-017-0890-9Lyngdoh T, Vuistiner P, Marques-Vidal P, Rousson V, Waeber G, Vollenweider P, Bochud M. Serum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach. PLoS One. 2012;7(6):e39321. doi: 10.1371/journal.pone.0039321Nitsch D, Molokhia M, Smeeth L, De Stavola B.L, Whittaker J.C, Leon D.A. Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. Am J Epidemiol. 2006;163(5):397-403. doi: 10.1093/aje/kwj062Doring A, Gieger C, Mehta D, Gohlke H, Prokisch H, Coassin S, Fischer G, Henke K, Klopp N, Kronenberg F, et al. SLC2A9 influences uric acid concentrations with pronounced sex - specific effects. Nat Genet. 2008;40(4):430-6. doi: 10.1038/ng.107Parsa A, Brown E, Weir M.R, Fink J.C, et al. Genotype - based changes in serum uric acid affect blood pressure. Kidney Int. 2012;81(5):502-7. doi: 10.1038/ki.2011.414Mallamaci F, Testa A, Leonardis D, Tripepi R, Pisano A, Spoto B, Sanguedolce M.C, Parlongo R.M, Tripepi G, Zoccali C. A polymorphism in the major gene regulating serum uric acid associates with clinic SBP and the white - coat effect in a family - based study. J Hypertens. 2014;32(8):1621-8. doi: 10.1097/HJH.0000000000000224Mallamaci F, Testa A, Leonardis D, Tripepi R, Pisano A, Spoto B, Sanguedolce M.C, Parlongo R.M, Tripepi G, Zoccali C. A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: a family - based study. Am J Kidney Dis. 2015;65(2):294-302. doi: 10.1038/ki.2011.414Palmer T.M, Nordestgaard B.G, Benn M, Tybjaerg-Hansen A, Davey Smith G, Lawlor D.A, Timpson N.J. Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts. BMJ. 2013;347:f4262. doi: 10.1136/bmj.f4262Mc Keigue P.M, Campbell H, Wild S, Vitart V, Hayward C, Rudan I, Wright A.F, Wilson J.F. Bayesian methods for instrumental variable analysis with genetic instruments (‘Mendelian randomization’): example with urate transporter SLC2A9 as an instrumental variable for effect of urate levels on metabolic syndrome. Int J Epidemiol. 2010;39(3):907-18. doi: 10.1093/ije/dyp397Kleber M.E, Delgado G, Grammer T.B, Silbernagel G, Huang J, Kramer B.K, Ritz E, Marz W. Uric acid and cardiovascular events: a Mendelian randomization study. J Am Soc Nephrol. 2015;26(11):2831-8. doi: 10.1681/ASN.2014070660Yan D, Wang J, Jiang F, et al. A causal relationship between uric acid and diabetic macrovascular disease in Chinese type 2 diabetes patients: a Mendelian randomization analysis. Int J Cardiol. 2016;214:194-9. doi: 10.1016 / j. ijcard.2016.03.206Yang Q, Kottgen A, Dehghan A, Smith A.V, Glazer N.L, Chen M.H, Chasman D.I, Aspelund T, Eiriksdottir G, Harris T.B, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet. 2010;3(6):523-30. doi: 10.1161/CIRCGENETICS.109.934455Keenan T, Zhao W, Rasheed A, Ho W.K, Malik R, Felix J.F, Young R, Shah N, Samuel M, Sheikh N, et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol. 2016;67(4):407-16. doi: 10.1016/j.jacc.2015.10.086Sedaghat S, Pazoki R, Uitterlinden A.G, Hofman A, Stricker B.H, Ikram M.A, Franco O.H, Dehghan A. Association of uric acid genetic risk score with blood pressure: the Rotterdam study. Hypertension. 2014;64(5):1061-6. doi: 10.1161/HYPERTENSIONAHA.114.03757HypertensionHiggins P, Dawson J, Lees K.R, Mc Arthur K, Quinn T.J, Walters M.R. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta - analysis. Cardiovasc Ther. 2012;30(4):217-26. doi:10.1111/j.1755-5922.2011.00277.xScheepers L.E, Wei F.F, Stolarz-Skrzypek K, Malyutina S, Tikhonoff V, Thijs L, Salvi E, Barlassina C, Filipovsky J, Casiglia E, et al. Xanthine oxidase gene variants and their association with blood pressure and incident hypertension: a population study. J Hypertens. 2016;34(11):2147-54. doi:10.1097/HJH0000000000001077Scheepers L.E, Boonen A, Pijnenburg W, Bierau J, Staessen J.A, Stehouwer C.D, Thijs C, Arts I.C. Associations of plasma uric acid and purine metabolites with blood pressure in children: the KOALA Birth Cohort Study. J Hypertens. 2017;35(5):982-93. doi: 10.1097/HJH.0000000000001270Schmitz B, Brand S.M. Uric acid and essential hypertension: the endothelial connection. J Hypertens. 2016;34(11):2138-9. doi: 10.1097/HJH.0000000000001109Hootman J.M, Helmick C.G. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 2006;54:226-9. doi: 10.1002/art. 21562Kuo C.F, Luo S.F. Gout: risk of premature death in gout unchanged for years. Nat Rev Rheumatol. 2017;13(4):200-1. doi: 10.1038/nrrheum.2017.27Culleton B.F, Larson M.G, Kannel W.B, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131(1):7-13. doi: 10.7326/0003-4819-131-1-199907060-00003So A, Thorens B. Uric acid transport and disease. J Clin Invest. 2010;120:1791-9. doi: 10.1172/JCI42344Rock K.L, Kataoka H, Lai J.J. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2013;9:13-23. doi: 10.1038/nrrheum.2012.143Kumar H.K.V.S, Marwaha V. Chronic Tophaceous Gout. Int J Med Health Sci. 2012;1(1):31-2.Liu S.C, Xia L, Zhang J, et al. Gout and risk of myocardial infarction: a systematic review and meta - analysis of cohort studies. PLoS ONE. 2015;10:e0134088.Clarson L.E, Hider S.L, Belcher J, et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74:642-7. doi: 10.1136/annrheumdis-2014-205252Choi H.K, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894-900. doi: 10.1161/CIRCULATIONAHA.107.703389Егоров И.В., Хитрик Н.М., Цурко В.В. Функциональное состояние нейтрофилов у пожилых больных хроническим подагрическим артритом в стадии обострения. Клиническая геронтология. 2008;(9):70-1.Perez-Ruiz F, Martinez-Indart L, Carmona L, Herrero-Beites A.M, Pijoan J.I, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73(1):177-82. doi: 10.1136/annrheumdis-2012-202421Edwards N.L. The role of hyperuricemia and gout in kidney and cardiovascular disease. Clev Clin J Med. 2008;75:13-6. doi:10.3949/ccjm.75.suppl5.s13Johnson R.J, Kang D.H, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183-90. doi: 10.1161/01.HYP.0000069700.62727.C5Briggs A.M, Cross M.J, Hoy D.G, et al. Musculoskeletal Health Conditions Represent a Global Threat to Healthy Aging: A Report for the 2015 World Health Organization World Report on Ageing and Health. Gerontologist. 2016;56(Suppl 2):S243-255. doi: 10.1093/geront/gnw002Clauw D.J. Diagnosing and treating chronic musculoskeletal pain based on the underlying mechanism(s). Best Pract Res Clin Rheumatol. 2015;29(1):6-19. doi: 10.1016/j.berh.2015.04.024Цурко В.В., Егоров И.В., Елисеева М.В. Подагра у пожилых пациентов, связь с коморбидностью. Практикующий врач сегодня. 2013;(1):2-8.Kuo C.F, Grainge M.J, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case - control study. Ann Rheum Dis. 2016;75(1):210-7. doi: 10.1136/annrheumdis-2014-206410Choi H.K, Ford E.S, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Ex - amination Survey. Arthritis Rheum. 2007;57(1):109-15. doi: 10.1002/art.22466Clarson L.E, Hider S.L, Belcher J, et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74:642-7. doi: 10.1136/annrheumdis-2014-205252Елисеев М.С., Новикова А.М. Коморбидность при подагре и гиперурикемии: распространенность, причины, перспективы уратснижающей терапии. Терапевтический архив. 2019;91(5):120-8. doi: 10.26442/00403660.2019. 05.000232Krishnan E, Baker J.F, Furst D.E, Schumacher H.R. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688-96. doi: 10.1002/art.22014De Vera M.A, Rahman M.M, Bhole V, Kopec J.A, Choi H.K. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population - based study. Ann Rheum Dis. 2010;69(6):1162-4. doi: 10.1136/ard.2009.122770Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open. 2012;2(1):e000282. doi: 10.1136/bmjopen-2011-000282Richette P, Latourte A, Bardin T. Cardiac and renal protective effects of urate - lowering therapy. Rheumatology (Oxford). 2018;57(suppl 1):i47-i50. doi: 10.1093/rheumatology/kex432Kuo C.F, Grainge M.J, Mallen C, Zhang W, Doherty M. Impact of gout on the risk of atrial fibrillation. Rheumatology (Oxford). 2016;55(4):721-8. doi: 10.1093/rheumatology/kev418Chang K, Yokose C, Tenner C, Oh C, Donnino R, Choy-Shan A, Pike V.C, Shah B.D, Lorin J.D, Krasnokutsky S, et al. Association between gout and aortic stenosis. Am J Med. 2017;130(2):230.e1-8. doi: 10.1016/j.amjmed.2016.09.005Stack A.G, Hanley A, Casserly L.F, Cronin C.J, Abdalla A.A, Kiernan T.J, Murthy B.V, Hegarty A, Hannigan A, Nguyen H.T. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM. 2013;106(7):647-58. doi: 10.1093/qjmed/hct083Schumacher H.R. Jr, Becker M.A, Wortmann R.L, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double - blind, parallel - group trial. Arthritis Rheum. 2008;59:1540-8. doi: 10.1002/art.24209Becker M.A, Schumacher H.R. Jr, Wortmann R.L, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-61. doi: 10.1056/NEJMoa050373Diaz-Torné C, Perez-Herrero N, Perez-Ruiz F. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol. 2015;27:164-9. doi:10.1097/BOR.0000000000000146Edwards N.L, So A. Emerging therapies for gout. Rheum Dis Clin North Am. 2014;40:375-87. doi: 10.1016/j.rdc.2014.01.013Terkeltaub R.A, Furst D.E, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty - four - hour outcome of the first multicenter, randomized, double - blind, placebo - controlled, parallel - group, dose - comparison colchicine study. Arthritis Rheum. 2010;62:1060-8. doi: 10.1002/art.27327Stamp L.K, O’Donnell J.L, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63:412-21. doi: 10.1002/art.30119Stamp L.K, Taylor W.J, Jones P.B, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64:2529-36. doi: 10.1002/art.34488Hung S.I, Chung W.H, Liou L.B, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102:4134-9. doi: 10.1073/pnas.0409500102Akkineni R, Tapp S, Tosteson A.N.A, et al. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach. J Rheumatol. 2014;41(4):739-48. doi: 10.3899/irheum.l21231Abeles A.M. Hyperuricemia, gout, and cardiovascular disease: an update. Curr Rheumatol Rep. 2015;17(3):13. doi: 10.1007//sll92601504952Lee J.E, Kim Y.G, Choi Y.H, et al. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension. 2006;47(5):962-7. doi: 10.1161/01.HYP.0000210550.97398x2Dalbeth N, Chen P, White M, et al. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Ann Rheum Dis. 2014;73:797-802. doi: 10.1136/annrheumdis-2013-203970Chen J.H, Wen C.P, Wu S.B, et al. Attenuating the mortality risk of high serum uric acid: the role of physical activity underused. Ann Rheum Dis. 2015;74:2034-42. doi:10.1136/annrheumdis-2014-205312Grimaldi-Bensouda L, Alperovitch A, Aubrun E, Danchin N, Rossignol M, Abenhaim L, Richette P. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2015;74(5):836-42. doi: 10.1136/annrheumdis-2012-202972De Abajo F.J, Gil M.J, Rodriguez A, Garcia-Poza P, Alvarez A, Bryant V, Garcia-Rodriguez L.A. Allopurinol use and risk of non - fatal acute myocardial infarction. Heart. 2015;101(9):679-85. doi: 10.1136/heartjnl-2014-306670Larsen K.S, Pottegard A, Lindegaard H.M, Hallas J. Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a cohort study. Am J Med. 2016;129(3):299-306. doi: 10.1016/j.amjmed.2015.11.003Zhang J, Dierckx R, Mohee K, Clark A.L, Cleland J.G. Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta - analysis. ESC Heart Fail. 2017;4(1):40-5. doi: 10.1002/ehf2.12112Kok V.C, Horng J.T, Chang W.S, Hong Y.F, Chang T.H. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population - based matched - cohort study. PLoS One. 2014;9(6):e99102. doi: 10.1371/journal.pone.0099102Borghi C, Tykarski A, Widecka K, et al. Expert consensus for diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J. 2018;25(5):545-64. doi: 10.5603/CJ.2018.0116Keenan R.T, O’Brien W.R, Lee K.H, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155-63. doi: 10.1016/j.amjmed.2010.09.012Nidorf S.M, Eikelboom J.W, Budgeon C.A, et al. Low - dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404-10. doi: 10.1016/j.jacc.2012.10.027Deftereos S, Giannopoulos G, Raisakis K, et al. Colchicine treatment for the prevention of baremetal stent restenosis in diabetic patients. J Am Coll Cardiol. 2013;61:1679-85. doi: 10.1016/j.jacc.2013.01.055Rothenbacher D, Primatesta P, Ferreira A, et al. Frequency and risk factors of gout flares in a large population - based cohort of incident gout. Rheumatology (Oxford). 2011;50:973-81. doi: 10.1093/rheumatology/keq363Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol. 2011;23:156-60. doi: 10.1097/BOR.0b013e3283432d35Feig D.I, Soletsky B, Johnson R.J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924-32. doi: 10.1001/jama.300.8.924Soletsky B, Feig D.I. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60(5):1148-56. doi: 10.1001/jama.300.8.924Mc Mullan C.J, Borgi L, Fisher N, Curhan G, Forman J. Effect of uric acid lowering on renin - angiotensin - system activation and ambulatory BP: a randomized controlled trial. Clin J Am Soc Nephrol. 2017;12(5):807-16. doi: 10.2215/CJN.10771016Poudel D.R, Karmacharya P, Donato A. Risk of acute gout among active smokers: data from nationwide inpatient sample. Clin Rheumatol. 2016;35(12):3015-8. doi: 10.1007/s10067-016-3415-6Gee Teng G, Pan A, Yuan J.M, Koh W.P. Cigarette smoking and the risk of incident gout in a prospective cohort study. Arthritis Care Res (Hoboken). 2016;68(8):1135-42. doi: 10.1002/acr.22821Wang W, Krishnan E. Cigarette smoking is associated with a reduction in the risk of incident gout: results from the Framingham Heart Study original cohort. Rheumatology (Oxford). 2015;54(1):91-5. doi: 10.1093/rheumatology/keu304Yu T.F, Gutman A.B. Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest. 1959;38(8):1298-315. doi: 10.1172/JCI103905Zhang Y, Neogi T, Chen C, Chaisson C, Hunter D.J, Choi H. Low - dose aspirin use and recurrent gout attacks. Ann Rheum Dis. 2014;73(2):385-90. doi: 10.1136/annrheumdis-2012-202589Choi H.K, Soriano L.C, Zhang Y, Rodriguez L.A. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case - control study. BMJ. 2012;344:d8190. doi: 10.1136/bmj.d8190Stamp L.K, Barclay M.L, O’Donnell J.L, Zhang M, Drake J, Frampton C, Chapman P.T. Furosemide increases plasma oxypurinol without lowering serum urate - a complex drug interaction: implications for clinical practice. Rheumatology (Oxford). 2012;51(9):1670-6. doi: 10.1093/rheumatology/kes091Knake C, Stamp L, Bahn A. Molecular mechanism of an adverse drug - drug interaction of allopurinol and furosemide in gout treatment. Biochem Biophys Res Commun. 2014;452(1):157-62. doi: 10.1016/j. bbrc.2014.08.068Ramsay L.E, Shelton J.R, Harrison I.R. Plasma uric acid and spironolactone response in healthy subjects. Br J Clin Pharmacol. 1977;4(2):247-9.Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti - hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis. 2003;62(6):572-5.Mustard J.F, Murphy E.A, Ogryzlo M.A, Smythe H.A. Blood coagulation and platelet economy in subjects with primary gout. Can Med Assoc J. 1963;89:1207-11. PMID: 14084698Yang C.Y, Chen C.H, Deng S.T, Huang C.S, Lin Y.J, Chen Y.J, Wu C.Y, Hung S.I, Chung W.H. Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population - based study in Taiwan. JAMA Intern Med. 2015;175(9):1550-7. doi: 10.1001/jamainternmed.2015.3536Perez-Ruiz F, Martínez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73(1):177-82. doi: 10.1136/annrheumdis-2012-202421Bhole V, Krishnan E. Gout and the heart. Rheum Dis Clin North Am. 2014;40:125-43.Agarwal V, Hans N, Messerli F.H. Effect of allopurinol on blood pressure: a systematic review and meta - analysis. J Clin Hypertens (Greenwich). 2013;15:435-42.Noman A, Ang D.S, Ogston S, et al. Effect of high - dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375:2161-7. doi: 10.1016/SO140-6736(10)60391-1Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug. Cardiol Rev. 2011;19:265-71.Thanassoulis G, Brophy J.M, Richard H, et al. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med. 2010;170:1358-64. doi: 10.1136/bmjopen-2011-000282